SCHEMBL4129742

SCHEMBL4129742

CC(C)NC(=O)N(CCCCNS(=O)(=O)c1ccc(Cl)cc1Cl)CCN(C(=O)O)c1ccccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 6/20 0.39
PTGES O14684 3/20 0.39
GAA P10253 1/20 0.38
FABP4 P15090 1/20 0.37
NR3C1 P04150 1/20 0.36
NR3C2 P08235 1/20 0.36
CCR1 P32246 1/20 0.36
ITGA1 P56199 2/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
ATM Q13315 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
TMEM97 Q5BJF2 1/20 0.34
SIGMAR1 Q99720 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136134 0.84 GAA (0.41) TRPV4PTGESGAAFABP4CCR1
SCHEMBL4145503 0.81 PTGES (0.41) TRPV4PTGESGAAFABP4
SCHEMBL4134999 0.81 GSTO1 (0.44) TRPV4GAACCR1ALDH1A1
SCHEMBL4142978 0.80 TRPV4 (0.38) TRPV4PTGESGAACCR1
SCHEMBL4129744 0.79 TRPV4 (0.39) TRPV4PTGESGAAFABP4CCR1
SCHEMBL4773183 0.78 GAA (0.40) TRPV4PTGESGAAFABP4CCR1
SCHEMBL13872455 0.78 ALDH1A1 (0.41) TRPV4GAACCR1KDM4EALDH1A1
SCHEMBL4136390 0.77 MAPK1 (0.40) TRPV4PTGESGAAFABP4CCR1
SCHEMBL4145501 0.77 PTGES (0.39) TRPV4PTGESGAAFABP4CCR1
SCHEMBL4135431 0.77 TRPV4 (0.41) TRPV4PTGESGAAFABP4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US claimed
EP-1940785-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SmithKline Beecham Corporation (US) 2008-07-09 EP claimed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO claimed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
EP-1940785-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SmithKline Beecham Corporation (US) 2008-07-09 EP disclosed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof TRPV4, TRPC4, TRPV1 TRPV4 1/4885PTGES 1099/4885GAA 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.